SU738622A1 - Method of preparing modified globulin - Google Patents
Method of preparing modified globulin Download PDFInfo
- Publication number
- SU738622A1 SU738622A1 SU772544365A SU2544365A SU738622A1 SU 738622 A1 SU738622 A1 SU 738622A1 SU 772544365 A SU772544365 A SU 772544365A SU 2544365 A SU2544365 A SU 2544365A SU 738622 A1 SU738622 A1 SU 738622A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- solution
- temperature
- globin
- blood cells
- centrifuged
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
(54) СПОСОБ ПОЛУЧЕНИЯ МОДИФИЦИРОВАННОГО ГЛОБИНА(54) METHOD FOR OBTAINING A MODIFIED GLOBIN
1one
Изобретение относитс к медицинской промышленности и касаетс получени белковых препаратов - плазмозаменителей .FIELD OF THE INVENTION The invention relates to the medical industry and relates to the preparation of protein preparations - plasma substitutes.
Известен способ получений модйфи- 5 цированнрго глобина из эритроцитов донорской крови путем отмывани эритроцитов от остатков плазменных белков и лейкоцитов, гемолиза эритроцитов , удалени стромы, выделени гло- 10 бин-гидрохлорида, щелочного гидролиза с последующей нейтрализацией щелочного раствора глобина, очисткой и i стерилизацией 1.A method of obtaining modyfi- 5 tsirovannrgo globin from blood erythrocytes by washing the erythrocytes of residual plasma proteins and white blood cells, red blood cells hemolysis, removing stroma, separating glo- bin 10-hydrochloride, alkaline hydrolysis followed by neutralization with an alkali solution globin, purification and sterilization i 1 .
Однако известный способ вл етс 5 трудоемким и выход глобина состгш-л ет 61%.However, the known method is 5 labor intensive and the yield of globin is 61%.
Целью изобретени вл етс упрощение технологии производства и повышение выхода целевого продукта. 20The aim of the invention is to simplify the production technology and increase the yield of the target product. 20
Эта цель достигаетс тем, что рН раствора гемоглобина освобожденного от стромы довод т до 2,0-2,4 при температуре , добавл ют раствор перекиси водорода, повышаюттемпера- 25 туру до 50-54с, провод т гидролиз при рН 12-13, центрифугируют, добавл ют этанол ,при температуре -5-7 С и при рН 5,7-5,9, центрифугируют, добавл ют глюкозу. 30This goal is achieved by adjusting the pH of the hemoglobin solution released from the stroma to 2.0-2.4 at a temperature, adding a solution of hydrogen peroxide, increasing the temperature to 50-54 ° C, hydrolysis at pH 12-13, centrifuging ethanol is added, at a temperature of -5-7 ° C and at pH 5.7-5.9, centrifuged, glucose is added. thirty
Способ осуществл ют следующим образом .The method is carried out as follows.
Пример. Эритроциты крови человека любых сроков хранени одной или всех групп крови (смешанные), содержащие один из обычных цитратныХ антикоагул нтоб, трижды отмывают физиологическим раствором хлористого натри , использу дл этой цели центрифугирование при 2500-3000 об/мин при температуре . Лейкоцитарную пленку удал ют сифоном. Отмывание провод т из расчета 2 объема 0,9%-ного раствора хлористого натри на 1 объем эритроцитов.Example. Erythrocytes of human blood of any storage time for one or all blood groups (mixed), containing one of the usual citrate anticoagulants, are washed three times with physiological saline solution, using centrifugation at 2500-3000 rpm for this purpose at a temperature. The leukocyte film is removed by siphon. Washing is carried out at the rate of 2 volumes of 0.9% sodium chloride solution per 1 volume of erythrocytes.
Отмытые эритроциты помещают в реIактор . К 1 объему эритроцитов добавл ют 2 объема апирогенной Охлажден . ной до 4°С воды и оставл ют сто ть в течение 1 часа дл протекани гемолиза . Затем довод т рН раствора до 5,,1 свежеприготовленным 1 н. раствором сол ной кислоты при перемешивании в течение 60-90 минут. При этих услови х из гемолизата выпадает в осадок строма эритроцитов. ДЛ ее удалени смесь центрифугируют при температуре в суперцентрифуге при 15000-20000-об/мин или в стаканчиковой - при 2500-3000 об/мин.Washed red blood cells are placed in the reactor. To 1 volume of red blood cells, add 2 volumes of pyrogen-free Cooled. water up to 4 ° C and allowed to stand for 1 hour for hemolysis. Then the pH of the solution is adjusted to 5,, 1 freshly prepared 1N. solution of hydrochloric acid with stirring for 60-90 minutes. Under these conditions, the erythrocyte stroma precipitates from the hemolysate. To remove it, the mixture is centrifuged at a temperature in a supercentrifuge at 15,000-20000-rpm or in a glass bowl at 2500-3000 rpm.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU772544365A SU738622A1 (en) | 1977-08-08 | 1977-08-08 | Method of preparing modified globulin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU772544365A SU738622A1 (en) | 1977-08-08 | 1977-08-08 | Method of preparing modified globulin |
Publications (1)
Publication Number | Publication Date |
---|---|
SU738622A1 true SU738622A1 (en) | 1980-06-05 |
Family
ID=20733385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU772544365A SU738622A1 (en) | 1977-08-08 | 1977-08-08 | Method of preparing modified globulin |
Country Status (1)
Country | Link |
---|---|
SU (1) | SU738622A1 (en) |
-
1977
- 1977-08-08 SU SU772544365A patent/SU738622A1/en active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Weiss | Platelet aggregation, adhesion and adenosine diphosphate release in thrombopathia (platelet factor 3 deficiency): a comparison with Glanzmann's thrombasthenia and von Willebrand's disease | |
USRE29698E (en) | Stabilization of AHF using heparin | |
US4158544A (en) | Process for preparing a biological composition for use as a reference control in diagnostic analysis | |
Wexler et al. | III. The Fate of Citrate in Erythroblastotic Infants Treated with Exchange Transfusion | |
Lepore et al. | Plasmapheresis with plasma exchange in hepatic coma: II. Fulminant viral hepatitis as a systemic disease | |
DK155568B (en) | PROCEDURE FOR STABILIZING THE COAGULATION FACTORS II, VIII, XIII AND ANTITHROMBINE III AND THE PLASMINOGEN AND THAT IT IS FIBRINOGEN-FREE AND FREE OF THE RISK OF HEPATITIS TRANSFER | |
Moyle et al. | Purification of the isocitric enzyme (triphosphopyridine nucleotide-linked isocitric dehydrogenase–oxalosuccinic carboxylase | |
Caldwell et al. | Crystalline Pancreatic Amylase. II. Improved Method for its Preparation from Hog Pancreas Glands and Additional Studies of its Properties1 | |
US4294824A (en) | Extracts of the hemopoietic system | |
JPH0339080B2 (en) | ||
Friedman et al. | Serum aldolase in the neonatal period: including a colorimetric determination of aldolase by standardization with dihydroxyacetone | |
SU738622A1 (en) | Method of preparing modified globulin | |
Hautekeete et al. | Purpura fulminans in pneumococcal sepsis | |
Dewey et al. | Studies on suramin (Antrypol: Bayer 205): 5. The combination of the drug with the plasma and other proteins | |
CN103145800B (en) | Centipede zymolyte anti-thrombus polypeptide | |
CN109913411A (en) | It is effectively improved the preparation method of the immunocyte of marrow stromal cell | |
Boursnell et al. | Studies on Bayer 205 (Germanin) and Antrypol: The retention of the drug in the animal body | |
CS208735B2 (en) | Method of making the pure heparine | |
Meleney et al. | POST-TRANSFUSION REACTIONS: A REVIEW OF 280 TRANSFUSIONS PERFORMED IN THE WARDS OF PRESBYTERIAN HOSPITAL, NEW YORK CITY. | |
US2921000A (en) | Thromboplastin | |
CN107488213B (en) | warfarin-4-O-acetyl-YIGSK, its synthesis, pharmacological activity and application | |
JPS6396132A (en) | Anticoagulation substance and production thereof | |
Aziz et al. | Congenital deficiency of fibrin-stabilizing factor (factor XIII): a report of four cases (two families) and family members | |
RU2045267C1 (en) | Method for production of hemine | |
CN110551176B (en) | LDV modified S, R-heptacyclic aldehyde, and synthesis, activity and application thereof |